Al Mamun Abu Amar M, Humayun M Zafri
University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Department of Microbiology and Molecular Genetics, International Center for Public Health, 225 Warren Street, Newark, NJ 07101-1709, USA.
Mutat Res. 2006 Jan 29;593(1-2):164-76. doi: 10.1016/j.mrfmmm.2005.07.016. Epub 2005 Sep 19.
Escherichia coli DNA polymerase II (pol-II) is a highly conserved protein that appears to have a role in replication restart, as well as in translesion synthesis across specific DNA adducts under some conditions. Here, we have investigated the effects of elevated expression of pol-II (without concomitant SOS induction) on translesion DNA synthesis and mutagenesis at 3,N(4)-ethenocytosine (varepsilonC), a highly mutagenic DNA lesion induced by oxidative stress as well as by exposure to industrial chemicals such as vinyl chloride. In normal cells, survival of transfected M13 single-stranded DNA bearing a single varepsilonC residue (varepsilonC-ssDNA) is about 20% of that of control DNA, with about 5% of the progeny phage bearing a mutation at the lesion site. Most mutations are C-->A and C-->T, with a slight predominance of transversions over transitions. In contrast, in cells expressing elevated levels of pol-II, survival of varepsilonC-ssDNA is close to 100%, with a concomitant mutation frequency of almost 99% suggesting highly efficient translesion DNA synthesis. Furthermore, an overwhelming majority of mutations at varepsilonC are C-->T transitions. Purified pol-II efficiently catalyzes translesion synthesis at varepsilonC in vitro, accompanied by high levels of mutagenesis with the same specificity. These results suggest that the observed in vivo effects in pol-II over-expressing cells are due to pol-II-mediated DNA synthesis. Introduction of mutations in the carboxy terminus region (beta interaction domain) of polB eliminates in vivo translesion synthesis at varepsilonC, suggesting that the ability of pol-II to compete with pol-III requires interaction with the beta processivity subunit of pol-III. Thus, pol-II can compete with pol-III for translesion synthesis.
大肠杆菌DNA聚合酶II(pol-II)是一种高度保守的蛋白质,似乎在复制重新启动中发挥作用,并且在某些条件下,在跨越特定DNA加合物的跨损伤合成中也发挥作用。在此,我们研究了pol-II表达升高(无伴随的SOS诱导)对3,N(4)-乙烯基胞嘧啶(εC)处的跨损伤DNA合成和诱变的影响,εC是一种由氧化应激以及接触工业化学品如氯乙烯诱导产生的高度诱变的DNA损伤。在正常细胞中,携带单个εC残基的转染M13单链DNA(εC-ssDNA)的存活率约为对照DNA的20%,约5%的子代噬菌体在损伤位点发生突变。大多数突变是C→A和C→T,颠换略多于转换。相比之下,在表达升高水平pol-II的细胞中,εC-ssDNA的存活率接近100%,同时突变频率几乎为99%,表明跨损伤DNA合成效率很高。此外,εC处绝大多数突变是C→T转换。纯化的pol-II在体外能有效催化εC处的跨损伤合成,并伴有高水平的具有相同特异性的诱变。这些结果表明,在pol-II过表达细胞中观察到的体内效应是由于pol-II介导的DNA合成。在polB的羧基末端区域(β相互作用结构域)引入突变可消除体内εC处的跨损伤合成,这表明pol-II与pol-III竞争的能力需要与pol-III的β持续性亚基相互作用。因此,pol-II可以与pol-III竞争进行跨损伤合成。